Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,599
  • Shares Outstanding, K 17,553
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,210 K
  • EBIT $ -76 M
  • EBITDA $ -78 M
  • 60-Month Beta 2.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12

Options Overview Details

View History
  • Implied Volatility 210.56% (+16.99%)
  • Historical Volatility 55.83%
  • IV Percentile 93%
  • IV Rank 75.26%
  • IV High 256.83% on 10/17/25
  • IV Low 69.83% on 05/22/25
  • Expected Move (DTE 16) 0.78 (9.65%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 140
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,989
  • Open Int (30-Day) 3,882
  • Expected Range 7.32 to 8.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.78
  • Number of Estimates 7
  • High Estimate -1.19
  • Low Estimate -3.57
  • Prior Year -0.78
  • Growth Rate Est. (year over year) -128.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.97 +2.01%
on 12/19/25
11.64 -30.15%
on 12/11/25
-3.41 (-29.55%)
since 11/28/25
3-Month
7.97 +2.01%
on 12/19/25
20.56 -60.46%
on 10/20/25
-4.52 (-35.73%)
since 09/30/25
52-Week
4.64 +75.22%
on 04/07/25
20.56 -60.46%
on 10/20/25
-3.95 (-32.70%)
since 12/30/24

Most Recent Stories

More News
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss...

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release...

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 HNSCC registrational study planned to start mid-2026...

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be...

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals Announces Pricing of Public Offering

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing...

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals Announces Proposed Public Offering

NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans...

CRBP : 8.16 (+1.87%)
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 continues to demonstrate a favorable safety and tolerability profile Registrational studies planned to...

CRBP : 8.16 (+1.87%)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Abbott Laboratories (ABT) and Corbus Pharmaceuticals (CRBP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Abbott Laboratories (ABT – Research Report) and Corbus Pharmaceuticals (CRBP – Research...

CRBP : 8.16 (+1.87%)
ABT : 125.77 (-0.01%)
CI : 276.84 (+0.13%)
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy                                Company to host HNSCC KOL event to review and...

CRBP : 8.16 (+1.87%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 8.44
2nd Resistance Point 8.36
1st Resistance Point 8.18
Last Price 8.16
1st Support Level 7.92
2nd Support Level 7.84
3rd Support Level 7.66

See More

52-Week High 20.56
Fibonacci 61.8% 14.48
Fibonacci 50% 12.60
Fibonacci 38.2% 10.72
Last Price 8.16
52-Week Low 4.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar